At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults With Early Symptomatic Alzheimer's Disease
In Brief
A Phase 3 clinical trial evaluating Donanemab, Placebo, and 1 other intervention for Alzheimer's Disease and 7 related conditions. Active but no longer recruiting, targeting 1,175 participants across 49 sites in 2 countries.
Detailed Summary
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA. Approximately 375 additional participants will be enrolled in addendum 2. Addendum 3 includes a subset of participants from the main study to receive a single dose. The study will last approximately 91 weeks and include up to 26 visits in the main study.
Study Details
Timeline
Interventions
Administered IV
Administered IV
Administered IV